Immunomedics (NASDAQ:IMMU) is set to release its earnings data after the market closes on Wednesday, August 7th. Analysts expect Immunomedics to post earnings of ($0.31) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
Immunomedics (NASDAQ:IMMU) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.10). During the same quarter in the previous year, the company posted ($0.21) earnings per share. On average, analysts expect Immunomedics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Immunomedics stock traded down $0.50 during trading hours on Monday, hitting $13.32. The stock had a trading volume of 23,656 shares, compared to its average volume of 1,573,118. The company has a current ratio of 7.89, a quick ratio of 7.89 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $2.65 billion, a PE ratio of -13.02 and a beta of 1.98. Immunomedics has a one year low of $11.55 and a one year high of $26.99. The business has a 50 day moving average of $14.17.
In other Immunomedics news, Director Avoro Capital Advisors Llc bought 785,539 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was acquired at an average price of $12.19 per share, with a total value of $9,575,720.41. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bryan Ball bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The shares were acquired at an average cost of $13.35 per share, with a total value of $66,750.00. Following the purchase, the insider now directly owns 5,000 shares of the company’s stock, valued at $66,750. The disclosure for this purchase can be found here. Insiders have bought 4,976,078 shares of company stock valued at $66,108,902 over the last 90 days. 9.40% of the stock is owned by corporate insiders.
Several research firms have commented on IMMU. HC Wainwright reiterated a “buy” rating and issued a $28.00 target price on shares of Immunomedics in a research report on Monday, May 13th. Zacks Investment Research upgraded Immunomedics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Cowen set a $30.00 target price on Immunomedics and gave the company a “buy” rating in a research report on Wednesday, July 31st. ValuEngine upgraded Immunomedics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Finally, BidaskClub upgraded Immunomedics from a “sell” rating to a “hold” rating in a research report on Friday, June 28th. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Immunomedics has a consensus rating of “Buy” and an average target price of $28.45.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
See Also: What is Depreciation?
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.